These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 17006847)
21. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma. Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382 [TBL] [Abstract][Full Text] [Related]
22. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene]. Fitze G; Saeger HD; Roesner D; Schackert HK Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293 [TBL] [Abstract][Full Text] [Related]
24. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320 [TBL] [Abstract][Full Text] [Related]
25. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma]. Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799 [TBL] [Abstract][Full Text] [Related]
26. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan. Chang CF; Yang WS; Su YN; Wu IL; Chang TC J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294 [TBL] [Abstract][Full Text] [Related]
27. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075 [TBL] [Abstract][Full Text] [Related]
28. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438 [TBL] [Abstract][Full Text] [Related]
30. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. Skinner MA; Wells SA Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335 [TBL] [Abstract][Full Text] [Related]
31. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. Quayle FJ; Moley JF J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378 [TBL] [Abstract][Full Text] [Related]
32. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance. Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779 [TBL] [Abstract][Full Text] [Related]
33. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey. Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973 [TBL] [Abstract][Full Text] [Related]
34. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225 [TBL] [Abstract][Full Text] [Related]
35. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. Frank-Raue K; Raue F Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387 [TBL] [Abstract][Full Text] [Related]
36. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219 [TBL] [Abstract][Full Text] [Related]
37. Multiple endocrine neoplasia type 2. Lodish M Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668 [TBL] [Abstract][Full Text] [Related]
38. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Jimenez C; Gagel RF Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800 [TBL] [Abstract][Full Text] [Related]
39. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene]. Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805 [TBL] [Abstract][Full Text] [Related]
40. Sporadic and Familial Medullary Thyroid Carcinoma: A Retrospective Single Center Study on Presentation and Outcome. Prinzi A; Vella V; Bosco A; Mirone A; Russo M; Piticchio T; Di Benedetto G; Bartoloni G; Frasca F; Malandrino P Endocr Res; 2024; 49(4):179-185. PubMed ID: 39419111 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]